Yoon Jung Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yoon Jung Hwang has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Haeryoung Kim
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
4 shared publications - Hyejung Lee
Department of Pathology, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Su Jong Yu
Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
2 shared publications - Suk Kyun Hong
Department of Surgery, Seoul National University Hospital, Seoul, Korea
2 shared publications - Yangkyu Lee
Department of Pathology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul 06273, Korea
2 shared publications - Bo Yun Hur
Department of Radiology, Healthcare System Gangnam Center, Seoul National University Hospital, Seoul, Korea
1 shared publication
Latest Publications
- Open Access
- 15 November 2025
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 59 (6) , 444-452
Diagnostic value of cytology in detecting human papillomavirus–independent cervical malignancies: a nation-wide study in Korea
Background: Human papillomavirus (HPV) independent cervical malignancies (HPV-IDCMs) have recently been classified by the World Health Organization (WHO) 5th edition. These malignancies have historically received limited attention due to their rarity and the potential for evasion of HPV-based screening.Methods: We retrospectively reviewed 5,854 biopsy-confirmed cervical malignancies from 22 institutions over 3 years (July 2020–June 2023). Histologic classification followed the WHO guidelines. HPV independence was confirmed by dual negativity for p16 and HPV; discordant cases (p16-positive/HPV-negative) underwent additional HPV testing using paraffin-embedded tissue. Cytological results were matched sequentially to histological confirmation.Results: The prevalence of HPV-IDCM was 4.4% (257/5,854) overall and was 3.6% (208/5,805 cases) among primary cervical malignancy. Patient age of HPV-IDCM was 29 to 89 years (median, 57.79). Its histologic subtypes included primary adenocarcinoma (n = 116), endometrial adenocarcinoma (n = 35), squamous cell carcinoma (n = 72), metastatic carcinoma (n = 14), carcinoma, not otherwise specified (n = 10), neuroendocrine carcinoma (n = 3), and others (n = 7). Among 155 cytology-histological matched cases, the overall and primary Pap test detection rates were 85.2% (132/155) and 83.2% (104/125), respectively. The interval between cytology and histologic confirmation extended up to 38 months.Conclusions: HPV-IDCMs comprised 3.6% of primary cervical malignancies with a high detection rate via cytology (83.2%). These findings affirm the value of cytological screening, particularly in patients with limited screening history or at risk for HPV-independent lesions, and may guide future screening protocols.
- 15 November 2025
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 59 (6) , 444-452
Open AccessDiagnostic value of cytology in detecting human papillomavirus–independent cervical malignancies: a nation-wide study in Korea
Background: Human papillomavirus (HPV) independent cervical malignancies (HPV-IDCMs) have recently been classified by the World Health Organization (WHO) 5th edition. These malignancies have historically received limited attention due to their rarity and the potential for evasion of HPV-based screening.Methods: We retrospectively reviewed 5,854 biopsy-confirmed cervical malignancies from 22 institutions over 3 years (July 2020–June 2023). Histologic classification followed the WHO guidelines. HPV independence was confirmed by dual negativity for p16 and HPV; discordant cases (p16-positive/HPV-negative) underwent additional HPV testing using paraffin-embedded tissue. Cytological results were matched sequentially to histological confirmation.Results: The prevalence of HPV-IDCM was 4.4% (257/5,854) overall and was 3.6% (208/5,805 cases) among primary cervical malignancy. Patient age of HPV-IDCM was 29 to 89 years (median, 57.79). Its histologic subtypes included primary adenocarcinoma (n = 116), endometrial adenocarcinoma (n = 35), squamous cell carcinoma (n = 72), metastatic carcinoma (n = 14), carcinoma, not otherwise specified (n = 10), neuroendocrine carcinoma (n = 3), and others (n = 7). Among 155 cytology-histological matched cases, the overall and primary Pap test detection rates were 85.2% (132/155) and 83.2% (104/125), respectively. The interval between cytology and histologic confirmation extended up to 38 months.Conclusions: HPV-IDCMs comprised 3.6% of primary cervical malignancies with a high detection rate via cytology (83.2%). These findings affirm the value of cytological screening, particularly in patients with limited screening history or at risk for HPV-independent lesions, and may guide future screening protocols.
- Open Access
- 8 January 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (2) , 275-285
Membranous Overexpression of Fibronectin Predicts Microvascular Invasion and Poor Survival Outcomes in Patients with Hepatocellular Carcinoma
Yoon Jung Hwang, Hyejung Lee, Suk Kyun Hong, Su Jong Yu, Haeryoung Kim. Gut and Liver 2025;19:275-85. https://doi.org/10.5009/gnl240254
- 8 January 2025
- Published by The Editorial Office of Gut and Liver in Gut and Liver
- Vol. 19 (2) , 275-285
Open AccessMembranous Overexpression of Fibronectin Predicts Microvascular Invasion and Poor Survival Outcomes in Patients with Hepatocellular Carcinoma
Yoon Jung Hwang, Hyejung Lee, Suk Kyun Hong, Su Jong Yu, Haeryoung Kim. Gut and Liver 2025;19:275-85. https://doi.org/10.5009/gnl240254
- 11 November 2024
- Published by Wiley in Histopathology
- Vol. 86 (4) , 547-558
Correlation between CTNNB1 mutation status and tumour phenotype in hepatitis B virus‐related hepatocellular carcinoma
Aims: The frequency of CTNNB1 mutation, one of the most frequent genetic events in hepatocellular carcinoma (HCC), is lower in Asian countries and in hepatitis B virus (HBV)‐related HCCs. In this study, we evaluated the prevalence and types of CTNNB1‐mutation in HBV‐related HCC and correlated the molecular status with the histomorphological and immunohistochemical features.Methods and results: A total of 108 consecutive cases of treatment‐naïve, surgically resected HBV‐related HCCs were selected. Targeted sequencing for CTNNB1 exons 3, 7 and 8 was performed, and the results were correlated with the expression pattern of glutamine synthetase (GS), nuclear β‐catenin expression status and the histomorphological characteristics of the tumour. CTNNB1 mutations were identified in 13% of HBV‐related HCCs; of these cases, mutations were found in D32‐S37 (7%), T41 (4%) and S45 (2%) of exon 3. None of the HCCs demonstrated alterations in exons 7 and 8. CTNNB1 mutation was strongly associated with diffuse strong GS expression (P < 0.001), nuclear β‐catenin expression (P < 0.001) and the classic CTNNB1 morphology (P = 0.038). Diffuse strong GS expression was observed in 78.6% of the CTNNB1‐mutated HCCs, and nuclear β‐catenin expression was identified in 64.3% of these cases. The classic CTNNB1 morphology was observed in 57% of all CTNNB1‐mutated HCCs. Furthermore, programmed death‐ligand 1 (PD‐L1) was less frequently expressed in HCCs with classic CTNNB1 morphology.Conclusions: CTNNB1 mutation was observed in 13% of HBV‐related HCCs in this Korean cohort, and was associated with diffuse strong GS expression, nuclear β‐catenin expression and classic CTNNB1 morphology.
- 11 November 2024
- Published by Wiley in Histopathology
- Vol. 86 (4) , 547-558
Correlation between CTNNB1 mutation status and tumour phenotype in hepatitis B virus‐related hepatocellular carcinoma
Aims: The frequency of CTNNB1 mutation, one of the most frequent genetic events in hepatocellular carcinoma (HCC), is lower in Asian countries and in hepatitis B virus (HBV)‐related HCCs. In this study, we evaluated the prevalence and types of CTNNB1‐mutation in HBV‐related HCC and correlated the molecular status with the histomorphological and immunohistochemical features.Methods and results: A total of 108 consecutive cases of treatment‐naïve, surgically resected HBV‐related HCCs were selected. Targeted sequencing for CTNNB1 exons 3, 7 and 8 was performed, and the results were correlated with the expression pattern of glutamine synthetase (GS), nuclear β‐catenin expression status and the histomorphological characteristics of the tumour. CTNNB1 mutations were identified in 13% of HBV‐related HCCs; of these cases, mutations were found in D32‐S37 (7%), T41 (4%) and S45 (2%) of exon 3. None of the HCCs demonstrated alterations in exons 7 and 8. CTNNB1 mutation was strongly associated with diffuse strong GS expression (P < 0.001), nuclear β‐catenin expression (P < 0.001) and the classic CTNNB1 morphology (P = 0.038). Diffuse strong GS expression was observed in 78.6% of the CTNNB1‐mutated HCCs, and nuclear β‐catenin expression was identified in 64.3% of these cases. The classic CTNNB1 morphology was observed in 57% of all CTNNB1‐mutated HCCs. Furthermore, programmed death‐ligand 1 (PD‐L1) was less frequently expressed in HCCs with classic CTNNB1 morphology.Conclusions: CTNNB1 mutation was observed in 13% of HBV‐related HCCs in this Korean cohort, and was associated with diffuse strong GS expression, nuclear β‐catenin expression and classic CTNNB1 morphology.
- Open Access
- 15 September 2021
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (5) , 338-348
Prognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
Background: Preoperative locoregional treatment (LRT) for hepatocellular carcinoma (HCC) often induces intratumoral necrosis without affecting the overall tumor size, and residual viable tumor size (VTS) on imaging is an important clinical parameter for assessing post-treatment response. However, for surgical specimens, it is unclear whether the VTS would be more relevant to prognosis compared to total tumor size (TTS).Methods: A total of 142 surgically resected solitary HCC cases were retrospectively reviewed. The TTS and VTS were assessed by applying the modified Response Evaluation Criteria in Solid Tumors method to the resected specimens, and correlated with the clinicopathological features and survival.Results: As applying VTS, 13/142 cases (9.2%) were down-staged to ypT1a. Although the survival analysis results for overall survival according to TTS or VTS were similar, VTS was superior to predict disease-free survival (DFS; p = .023) compared to TTS (p = .08). In addition, multivariate analysis demonstrated VTS > 2 cm to be an independent predictive factor for decreased DFS (p = .001). In the subpopulation of patients with LRT (n = 54), DFS in HCCs with TTS or VTS > 2 cm were significantly shorter than those with TTS or VTS ≤ 2 cm (p = .047 and p = .001, respectively). Interestingly, HCCs with TTS > 2 cm but down-staged to VTS ≤ 2 cm after preoperative LRT had similar survival to those with TTS ≤ 2 cm.Conclusions: Although the prognostic impact of tumor size was similar regardless of whether TTS or VTS was applied, reporting VTS may help to increase the number of candidates for surgery in HCC patients with preoperative LRT.
- 15 September 2021
- Published by The Korean Society of Pathologists and The Korean Society for Cytopathology in Journal of Pathology and Translational Medicine
- Vol. 55 (5) , 338-348
Open AccessPrognostic significance of viable tumor size measurement in hepatocellular carcinomas after preoperative locoregional treatment
Background: Preoperative locoregional treatment (LRT) for hepatocellular carcinoma (HCC) often induces intratumoral necrosis without affecting the overall tumor size, and residual viable tumor size (VTS) on imaging is an important clinical parameter for assessing post-treatment response. However, for surgical specimens, it is unclear whether the VTS would be more relevant to prognosis compared to total tumor size (TTS).Methods: A total of 142 surgically resected solitary HCC cases were retrospectively reviewed. The TTS and VTS were assessed by applying the modified Response Evaluation Criteria in Solid Tumors method to the resected specimens, and correlated with the clinicopathological features and survival.Results: As applying VTS, 13/142 cases (9.2%) were down-staged to ypT1a. Although the survival analysis results for overall survival according to TTS or VTS were similar, VTS was superior to predict disease-free survival (DFS; p = .023) compared to TTS (p = .08). In addition, multivariate analysis demonstrated VTS > 2 cm to be an independent predictive factor for decreased DFS (p = .001). In the subpopulation of patients with LRT (n = 54), DFS in HCCs with TTS or VTS > 2 cm were significantly shorter than those with TTS or VTS ≤ 2 cm (p = .047 and p = .001, respectively). Interestingly, HCCs with TTS > 2 cm but down-staged to VTS ≤ 2 cm after preoperative LRT had similar survival to those with TTS ≤ 2 cm.Conclusions: Although the prognostic impact of tumor size was similar regardless of whether TTS or VTS was applied, reporting VTS may help to increase the number of candidates for surgery in HCC patients with preoperative LRT.
- 1 September 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 300 (3) , 572-582
Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery
Proliferative hepatocellular carcinoma was an independent factor for poor survival with increased risk of intrahepatic and extrahepatic metastases, and rim arterial phase hyperenhancement at gadoxe... Background Hepatocellular carcinomas (HCCs) are heterogeneous neoplasms, and the prognosis varies based on the subtype. Two broad molecular classes of HCC have been proposed: a proliferative and a ...
- 1 September 2021
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 300 (3) , 572-582
Gadoxetate-enhanced MRI Features of Proliferative Hepatocellular Carcinoma Are Prognostic after Surgery
Proliferative hepatocellular carcinoma was an independent factor for poor survival with increased risk of intrahepatic and extrahepatic metastases, and rim arterial phase hyperenhancement at gadoxe... Background Hepatocellular carcinomas (HCCs) are heterogeneous neoplasms, and the prognosis varies based on the subtype. Two broad molecular classes of HCC have been proposed: a proliferative and a ...